All In Biotech

Drug Trial Radar · NCT07674290

Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity

Real-World Effectiveness, Safety and Patient-reported Outcomes of Setmelanotide in Patients With Bardet-Biedl Syndrome: A Prospective Mono Centric Observational Interventional Study

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 1, 2023

Primary completion

Dec 31, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Tom HühneAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Rhythm Pharmaceuticals, Inc.
First posted
Jun 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bardet-Biedl syndrome (BBS) and other rare disorders associated with impairment of the melanocortin-4 receptor (MC4R) pathway are characterized by severe early-onset obesity, hyperphagia, and substantial morbidity. Setmelanotide, an MC4R agonist, is approved in Europe for selected genetic obesity disorders and reimbursed in Germany for eligible patients. This study aims to evaluate the effectiveness, safety, treatment persistence, metabolic outcomes, and patient-reported outcomes of Setmelanotide under real-world conditions. The registry is designed to allow future inclusion of additional MC4R agonists as they become approved and clinically available. The study will primarily be conducted at University Hospital Essen and will collect longitudinal routine clinical data from pediatric and adult patients receiving MC4R agonist therapy according to approved indications.

Conditions

  • Bardet Biedl Syndrome (BBS)
  • Bardet Biedl Syndrome
  • Bardet-Biedl Syndrome (BBS)
  • Alstrom Syndrome

Interventions

  • SetmelanotideDrug

    Administration according to approved product labeling and treating physician discretion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in BMI z-scoreTime frame: Baseline to 12/24/36/48/60/72 months
  2. Impact on lipid profileTime frame: Baseline to 12/24/36/48/60/72 months
  3. Change in Hepatic Fat AttenuationTime frame: Baseline to 12/24/36/48/60/72 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Essen, Deparment of Pediatrics II

    Essen, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.